Shots:
- Novartis has reported topline P-III (GCAptAIN) trial results on Cosentyx to treat adults with newly diagnosed or relapsing giant cell arteritis (GCA)
- The P-III (GCAptAIN) trial assessed efficacy & safety of Cosentyx (300 or 150mg) vs PBO, both in combination with a glucocorticoid taper regimen, in GCA pts across 27 countries
- In the trial, Cosentyx + 26wk. steroid taper did not meet its 1EP of sustained remission at Wk. 52 compared to PBO + 52wk. taper. However, Cosentyx showed superior outcomes for cumulative steroid dose & steroid-related toxicity; evaluation of full trial data is ongoing, with results to be reported in future
Ref: Prnewswire | Image: Novartis | Press Release
Related News:- Novartis Reports the Health Canada’s Approval of Kisqali (Ribociclib) for the Treatment of HR+/HER2- Early Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
